Justin R. LaClair

This study identifies loss of function mutations in the DNA pre-replication complex as a mechanism for PARP inhibitor resistance in BRCA-mutant prostate cancer, independent of reversion mutations.

This study shows that treatment timing affects the path to androgen receptor signaling inhibitor resistance in prostate cancer, with resistance arising through different mechanisms depending on the tumor context.